시장보고서
상품코드
253943

감염증 백신 시장의 사업제휴 : 계약 조건 및 합의 내용

Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials

발행일: | 리서치사: Current Partnering, a division of Wildwood Ventures Limited | 페이지 정보: 영문 450+ Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

감염증(Infectives) 관련 각종 계약--사업제휴(파트너십), 기타 자본거래 제휴--의 계약 조건 동향에 대해 분석하고, 최근의 각종 계약 동향, 대규모 계약 및 대형 제약기업의 계약 개요, 계약 종류·개발 단계·질환 구분·기술 구분별 디렉토리 등의 정보를 전해드립니다.

개요

제1장 서론

제2장 감염증 백신 관련 자본거래 동향

  • 개요
  • 감염증 백신 관련 사업제휴 : 과거 몇 년간 동향
  • 대형 제약기업의 감염증 백신 관련 자본거래 행동
  • 감염증 백신 관련 자본거래 행동에 적극적인 제약기업
  • 감염증 백신 관련 자본거래 : 거래 종류별
  • 감염증 백신 관련 자본거래 : 개발 단계별
  • 감염증 백신 관련 자본거래 : 적응증별
  • 감염증 백신 관련 자본거래 : 백신/보조제
  • 파트너십에 관한 공개된 거래 조건
  • 감염증 백신 관련 자본거래 구조 및 사례

제3장 대표적인 자본거래

  • 서론
  • 대표적인 자본거래(거래액 기준 순위)

제4장 대형 제약기업의 감염증 백신 관련 자본거래

  • 서론
  • 데이터 활용 방법에 대해
  • 대형 제약기업의 감염증 백신 관련 자본거래 : 기업 개요
    • Abbott
    • Astellas Pharma Inc.
    • Daiichi-Sankyo
    • Gilead Sciences
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Co
    • Novartis
    • Pfizer
    • Purdue
    • Sanofi
    • Takeda

제5장 대형 바이오테크놀러지 기업의 감염증 백신 관련 자본거래

제6장 감염증 백신 자본거래 기업 목록

  • 서론
  • 관련 기업 및 단체명(ABC순)
  • 임상시험 단계별
  • 거래 종류별
    • 자산 인수
    • 자산 양도
    • 대형 제약기업의 라이선스 계약(outlicensing)
    • 공동 개발
    • 공동 연구개발(R&D)
    • 공동 시장
    • 계약 서비스
    • 공동 프로모션
    • 공동 연구개발 계약(CRADA)
    • 크로스 라이선싱
    • 개발
    • 유통
    • 주식 구입
    • 평가
    • 부여
    • 합작투자
    • 라이선스 계약
    • 소송
    • 제조
    • OEM
    • 마케팅
    • 자재 이전
    • 옵션
    • 프로모션
    • 조사
    • 로열티 파이낸싱
    • 조정
    • 스핀아웃
    • 서브 라이선스
    • 공급
    • 기술 이전
    • 종결
    • 보상
  • 감염증 치료 영역
  • 관련 기술별

제7장 제휴 자료 센터

  • 온라인 파트너십
  • 파트너링 이벤트
  • 관련 자료

부록

도표

LSH 13.06.12

The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2015, including financial terms where available, including over 760 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2015. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2015. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2015. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide. Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials includes:

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 760 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2015
  • The leading infectious vaccines deals by value since 2015
  • Includes adjuvant deals and alliances since 2015

In Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 760 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of infectious vaccines deal trends since 2015
  • Access infectious vaccines deal headline, upfront, milestone and royalty data
  • Comprehensive access to over 760 links to actual infectious vaccines deals entered into by the world's biopharma companies
  • Identify leading infectious vaccines deals by value since 2015
  • Identify the most active infectious vaccines dealmakers since 2015
  • Insight into the terms included in infectious vaccines agreement
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking

  • 2.1. Introduction
  • 2.2. Infectious Vaccines partnering over the years
  • 2.3. Most active Infectious Vaccines dealmakers
  • 2.4. Infectious Vaccines partnering by deal type
  • 2.5. Infectious Vaccines partnering by therapy area
  • 2.6. Deal terms for Infectious Vaccines partnering
    • 2.6.1 Infectious Vaccines partnering headline values
    • 2.6.2 Infectious Vaccines deal upfront payments
    • 2.6.3 Infectious Vaccines deal milestone payments
    • 2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals

  • 3.1. Introduction
  • 3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers

  • 4.1. Introduction
  • 4.2. Most active Infectious Vaccines dealmakers
  • 4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Appendices

  • Appendix 1 - Infectious Vaccines deals by company A-Z
  • Appendix 2 - Infectious Vaccines deals by stage of development
  • Appendix 3 - Infectious Vaccines deals by deal type
  • Appendix 4 - Infectious Vaccines deals by therapy area
  • Appendix 5 - Deal type definitions
  • Appendix 6 - Further reading on dealmaking

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Infectious Vaccines partnering since 2015
  • Figure 2: Active Infectious Vaccines dealmaking activity since 2015
  • Figure 3: Infectious Vaccines partnering by deal type since 2015
  • Figure 4: Infectious Vaccines partnering by disease type since 2015
  • Figure 5: Infectious Vaccines deals with a headline value
  • Figure 6: Infectious Vaccines deals with an upfront value
  • Figure 7: Infectious Vaccines deals with a milestone value
  • Figure 8: Infectious Vaccines deals with a royalty rate value
  • Figure 9: Top Infectious Vaccines deals by value since 2015
  • Figure 10: Most active Infectious Vaccines dealmakers since 2015
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제